StreetInsider.com News Articles

ResMed (RMD) PT Lowered to $300 at UBS

Tue, 21 Jul 2026 08:57:33 -0400

UBS analyst David Low lowered the price target on ResMed (NYSE: RMD) to $300.00 (from $312.00) while maintaining a Buy rating.

The analyst commented, "We expect Resmed to report strong earnings growth supported by an 8.6% lift in sales and further gross margin expansion (UBSe 63%) due to improved pricing/mix. We assume US CPAP device volumes continue to moderate (UBSe ~5%), reflecting market maturity rather than a material GLP-1 headwind. Our sales estimates are in-line with consensus, with the expected EBIT and EPS beat largely driven by a strong gross margin outcome."

ResMed (RMD) PT Lowered to $300 at UBS

Tue, 21 Jul 2026 08:57:33 -0400

UBS analyst David Low lowered the price target on ResMed (NYSE: RMD) to $300.00 (from $312.00) while maintaining a Buy rating.

ResMed (RMD:AU) (RMD) PT Lowered to AUD35.80 at JPMorgan

Tue, 21 Jul 2026 08:42:36 -0400

JPMorgan analyst David Low lowered the price target on ResMed (RMD:AU) (NYSE: RMD) to AUD35.80 (from AUD37.10) while maintaining a Overweight rating.

ResMed (RMD:AU) (RMD) PT Lowered to AUD35.80 at JPMorgan

Tue, 21 Jul 2026 08:42:36 -0400

JPMorgan analyst David Low lowered the price target on ResMed (RMD:AU) (NYSE: RMD) to AUD35.80 (from AUD37.10) while maintaining a Overweight rating.

ResMed (RMD:AU) (RMD) PT Lowered to AUD35.80 at JPMorgan

Tue, 21 Jul 2026 08:42:36 -0400

JPMorgan analyst David Low lowered the price target on ResMed (RMD:AU) (NYSE: RMD) to AUD35.80 (from AUD37.10) while maintaining a Overweight rating.

ResMed (RMD:AU) (RMD) PT Lowered to AUD35.80 at JPMorgan

Tue, 21 Jul 2026 08:42:36 -0400

JPMorgan analyst David Low lowered the price target on ResMed (RMD:AU) (NYSE: RMD) to AUD35.80 (from AUD37.10) while maintaining a Overweight rating.

ResMed (RMD:AU) (RMD) PT Lowered to AUD40 at Canaccord

Tue, 21 Jul 2026 05:59:48 -0400

Canaccord analyst Paul Howard lowered the price target on ResMed (RMD:AU) (NYSE: RMD) to AUD40.00 (from AUD44.50) while maintaining a Buy rating.

ResMed (RMD:AU) (RMD) PT Lowered to AUD40 at Canaccord

Tue, 21 Jul 2026 05:59:48 -0400

Canaccord analyst Paul Howard lowered the price target on ResMed (RMD:AU) (NYSE: RMD) to AUD40.00 (from AUD44.50) while maintaining a Buy rating.

ResMed (RMD:AU) (RMD) PT Lowered to AUD40 at Canaccord

Tue, 21 Jul 2026 05:59:48 -0400

Canaccord analyst Paul Howard lowered the price target on ResMed (RMD:AU) (NYSE: RMD) to AUD40.00 (from AUD44.50) while maintaining a Buy rating.

ResMed (RMD:AU) (RMD) PT Lowered to AUD40 at Canaccord

Tue, 21 Jul 2026 05:59:48 -0400

Canaccord analyst Paul Howard lowered the price target on ResMed (RMD:AU) (NYSE: RMD) to AUD40.00 (from AUD44.50) while maintaining a Buy rating.

RBC Capital Downgrades ResMed (RMD) to Sector Perform

Thu, 16 Jul 2026 06:30:57 -0400

RBC Capital analyst Craig Wong-Pan downgraded ResMed (NYSE: RMD) from Outperform to Sector Perform with a price target of $234.00.

For an analyst ratings summary and ratings history on ResMed click here. For more ratings news on ResMed click here.

Shares of ResMed closed at $198.57 yesterday.

ResMed (RMD) PT Lowered to $220 at Mizuho

Wed, 15 Jul 2026 06:40:22 -0400

Mizuho analyst Anthony Petrone lowered the price target on ResMed (NYSE: RMD) to $220.00 (from $235.00) while maintaining a Outperform rating.

ResMed (RMD) PT Lowered to $217 at Baird

Tue, 14 Jul 2026 06:25:41 -0400

Baird analyst Jeff Johnson lowered the price target on ResMed (NYSE: RMD) to $217.00 (from $225.00) while maintaining a Neutral rating.

Citi Downgrades ResMed (RMD:AU) (RMD) to Neutral

Mon, 13 Jul 2026 03:19:50 -0400